Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Stoke Therapeutics stock | $22.65

Learn how to easily invest in Stoke Therapeutics stock.

Stoke Therapeutics Inc is a biotechnology business based in the US. Stoke Therapeutics shares (STOK) are listed on the NASDAQ and all prices are listed in US Dollars. Stoke Therapeutics employs 79 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Stoke Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – STOK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Stoke Therapeutics stock price (NASDAQ: STOK)

Use our graph to track the performance of STOK stocks over time.

Stoke Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$22.65
52-week range$21.42 - $71.58
50-day moving average $25.06
200-day moving average $31.07
Wall St. target price$62.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.90

Buy Stoke Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Stoke Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Stoke Therapeutics price performance over time

Historical closes compared with the close of $22.65 from 2021-10-18

1 week (2021-10-13) -1.56%
1 month (2021-09-20) -4.23%
3 months (2021-07-20) -31.96%
6 months (2021-04-20) -27.31%
1 year (2020-10-20) -40.78%
2 years (2019-10-18) 1.52%
3 years (2018-10-16) N/A
5 years (2016-10-16) N/A

Stoke Therapeutics financials

Gross profit TTM $0
Return on assets TTM -17.68%
Return on equity TTM -29.23%
Profit margin 0%
Book value $6.95
Market capitalisation $864.3 million

TTM: trailing 12 months

Shorting Stoke Therapeutics shares

There are currently 2.0 million Stoke Therapeutics shares held short by investors – that's known as Stoke Therapeutics's "short interest". This figure is 28.5% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Stoke Therapeutics shares can be evaluated.

Stoke Therapeutics's "short interest ratio" (SIR)

Stoke Therapeutics's "short interest ratio" (SIR) is the quantity of Stoke Therapeutics shares currently shorted divided by the average quantity of Stoke Therapeutics shares traded daily (recently around 130674.10832232). Stoke Therapeutics's SIR currently stands at 15.14. In other words for every 100,000 Stoke Therapeutics shares traded daily on the market, roughly 15140 shares are currently held short.

However Stoke Therapeutics's short interest can also be evaluated against the total number of Stoke Therapeutics shares, or, against the total number of tradable Stoke Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stoke Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Stoke Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.144% of the tradable shares (for every 100,000 tradable Stoke Therapeutics shares, roughly 144 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Stoke Therapeutics.

Find out more about how you can short Stoke Therapeutics stock.

Stoke Therapeutics share dividends

We're not expecting Stoke Therapeutics to pay a dividend over the next 12 months.

Stoke Therapeutics share price volatility

Over the last 12 months, Stoke Therapeutics's shares have ranged in value from as little as $21.42 up to $71.58. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Stoke Therapeutics's is 0.2877. This would suggest that Stoke Therapeutics's shares are less volatile than average (for this exchange).

Stoke Therapeutics overview

Stoke Therapeutics, Inc. , an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.

Frequently asked questions

What percentage of Stoke Therapeutics is owned by insiders or institutions?
Currently 46.116% of Stoke Therapeutics shares are held by insiders and 55.533% by institutions.
How many people work for Stoke Therapeutics?
Latest data suggests 79 work at Stoke Therapeutics.
When does the fiscal year end for Stoke Therapeutics?
Stoke Therapeutics's fiscal year ends in December.
Where is Stoke Therapeutics based?
Stoke Therapeutics's address is: 45 Wiggins Avenue, Bedford, MA, United States, 01730
What is Stoke Therapeutics's ISIN number?
Stoke Therapeutics's international securities identification number is: US86150R1077
What is Stoke Therapeutics's CUSIP number?
Stoke Therapeutics's Committee on Uniform Securities Identification Procedures number is: 86149C104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site